Weight Loss Drugs May Help Prevent Addiction and Overdose, Research Reveals
A groundbreaking study has found that weight loss medications, specifically GLP-1 receptor agonists such as Mounjaro and Ozempic, could potentially reduce the risk of individuals developing addictions to substances like alcohol, tobacco, cannabis, and cocaine. The research, published in the British Medical Journal, also suggests these drugs might lower the chances of overdose, hospitalisation, and death among those already using illicit substances.
How GLP-1 Drugs Influence Brain Pathways
GLP-1 receptor agonists, commonly used to treat type 2 diabetes and obesity, are believed to work by affecting the brain's reward pathways, thereby diminishing cravings. These medications mimic natural substances released after eating, helping users feel fuller and reducing the desire for addictive substances. The study analysed data from 606,434 US veterans with type 2 diabetes over up to three years, comparing outcomes between those on GLP-1s and those using other diabetes drugs like sodium-glucose cotransporter-2 inhibitors.
Key Findings on Addiction Risk Reduction
The results showed significant reductions in the risk of developing substance-related disorders among individuals with no prior history of addiction. Specifically, GLP-1s lowered the risk by 18% for alcohol-related issues, 14% for cannabis use, 20% for cocaine, 20% for nicotine, and 25% for opioids. For those already using substances, the drugs reduced the risk of overdose by 39%, emergency department visits by 31%, and mortality by 50%.
Expert Insights and Cautionary Notes
Professor Claire Anderson, President of the Royal Pharmaceutical Society, commented, "This study adds to emerging research exploring whether GLP-1 medicines may influence brain pathways involved in reward and addiction." However, she emphasised that as an observational study, it does not prove these medications can prevent or treat addiction, highlighting the need for further clinical trials to confirm direct effects.
Gareth Jones, Director of Corporate Affairs at the National Pharmacy Association, noted, "This is a significant study and shows that weight loss treatment may have potential to give important additional therapeutic benefits." He added that while more is understood about the long-term impacts, weight loss treatments can positively affect various health outcomes for eligible patients.
Challenges in Drug Rollout and Usage
Despite these potential benefits, Jones pointed out that the NHS's rollout of these drugs to obese individuals remains "painfully slow", despite obesity's significant health challenges. Additionally, a separate meta-analysis from Cambridge University, published in eClinical Medicine, found that most people who stop taking GLP-1s regain 60% of lost weight within a year and 75% eventually, sustaining only 25% long-term weight loss.
About half of users discontinue GLP-1s within a year, and 75% stop after two years, often due to side effects like nausea and high costs. A survey by Simple Online Pharmacy revealed that two-thirds of patients hide their usage from friends and family, fearing judgment and being labelled as "cheats", with 38% reporting criticism for taking the drugs.
Implications for Future Health Policies
This research underscores the potential dual benefits of GLP-1 drugs in managing both obesity and addiction risks, but it also highlights the need for improved access and support systems within healthcare frameworks. As studies continue to evolve, these findings could pave the way for new therapeutic approaches in public health strategies.
